[go: up one dir, main page]

CL2019001978A1 - Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo. - Google Patents

Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.

Info

Publication number
CL2019001978A1
CL2019001978A1 CL2019001978A CL2019001978A CL2019001978A1 CL 2019001978 A1 CL2019001978 A1 CL 2019001978A1 CL 2019001978 A CL2019001978 A CL 2019001978A CL 2019001978 A CL2019001978 A CL 2019001978A CL 2019001978 A1 CL2019001978 A1 CL 2019001978A1
Authority
CL
Chile
Prior art keywords
compounds
oxadiazol
methyl
formula
alzheimer
Prior art date
Application number
CL2019001978A
Other languages
English (en)
Inventor
Nicolas Jacques Francois Dreyfus
Peter James Lindsay-Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2019001978A1 publication Critical patent/CL2019001978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA I; O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, Y EL USO DE COMPUESTOS DE FÓRMULA I PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS NEURODEGENERATIVOS, TALES COMO LA ENFERMEDAD DE ALZHEIMER.
CL2019001978A 2017-01-27 2019-07-12 Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo. CL2019001978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27

Publications (1)

Publication Number Publication Date
CL2019001978A1 true CL2019001978A1 (es) 2019-12-13

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001978A CL2019001978A1 (es) 2017-01-27 2019-07-12 Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.

Country Status (36)

Country Link
US (1) US10081625B2 (es)
EP (1) EP3573983B1 (es)
JP (1) JP6738970B2 (es)
KR (1) KR102275338B1 (es)
CN (1) CN110198940B (es)
AR (1) AR110747A1 (es)
AU (1) AU2018213029B2 (es)
CA (1) CA3049141C (es)
CL (1) CL2019001978A1 (es)
CO (1) CO2019007711A2 (es)
CR (1) CR20190320A (es)
CY (1) CY1124257T1 (es)
DK (1) DK3573983T3 (es)
DO (1) DOP2019000187A (es)
EA (1) EA038368B1 (es)
EC (1) ECSP19053616A (es)
ES (1) ES2871949T3 (es)
HR (1) HRP20211011T1 (es)
HU (1) HUE054990T2 (es)
IL (1) IL267693B (es)
JO (1) JOP20190182B1 (es)
LT (1) LT3573983T (es)
MA (1) MA47368B1 (es)
MD (1) MD3573983T2 (es)
MX (1) MX387166B (es)
MY (1) MY197494A (es)
PE (1) PE20191406A1 (es)
PH (1) PH12019501707A1 (es)
PL (1) PL3573983T3 (es)
PT (1) PT3573983T (es)
RS (1) RS61979B1 (es)
SI (1) SI3573983T1 (es)
TW (1) TWI654978B (es)
UA (1) UA123472C2 (es)
WO (1) WO2018140299A1 (es)
ZA (1) ZA201904171B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893289T3 (es) 2014-08-28 2022-02-08 Asceneuron Sa Inhibidores de glucosidasa
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
KR20180132629A (ko) 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
WO2020028115A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company 5-methyl-4-fluoro-thiazol-2-yl compounds
CA3107788A1 (en) * 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
CA3110032A1 (en) 2018-08-22 2020-02-27 Asceneuron S.A. Succinate and fumarate acid addition salts of piperazine derivatives
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
JP7606960B2 (ja) 2018-09-19 2024-12-26 バイオジェン・エムエイ・インコーポレイテッド Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
WO2020117961A1 (en) 2018-12-05 2020-06-11 Biogen Ma Inc. Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3921316A1 (en) * 2019-02-04 2021-12-15 Biogen MA Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
BR112022011812A2 (pt) 2019-12-18 2022-08-30 Janssen Pharmaceutica Nv Compostos inibidores da oga
MX2022007654A (es) 2019-12-18 2022-07-19 Janssen Pharmaceutica Nv Compuestos inhibidores de la oga.
TW202220650A (zh) * 2020-07-23 2022-06-01 美商美國禮來大藥廠 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物
IL300365A (en) 2020-08-03 2023-04-01 Biogen Ma Inc Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor
CA3235104A1 (en) * 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
KR20240145486A (ko) 2022-02-03 2024-10-07 일라이 릴리 앤드 캄파니 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
CA2518839A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
CN101426777A (zh) * 2005-12-21 2009-05-06 先灵公司 用作组胺h3拮抗剂的苯氧基哌啶及其类似物
EP2139332A4 (en) * 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
US9732065B2 (en) * 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
ES2893289T3 (es) * 2014-08-28 2022-02-08 Asceneuron Sa Inhibidores de glucosidasa
EP3389658B1 (en) 2015-12-18 2020-11-25 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
AU2017378186A1 (en) * 2016-12-16 2019-06-13 Janssen Pharmaceutica Nv Monocyclic OGA inhibitor compounds

Also Published As

Publication number Publication date
CR20190320A (es) 2019-08-27
CN110198940A (zh) 2019-09-03
HUE054990T2 (hu) 2021-10-28
US20180215751A1 (en) 2018-08-02
KR102275338B1 (ko) 2021-07-12
ES2871949T3 (es) 2021-11-02
TWI654978B (zh) 2019-04-01
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
IL267693A (en) 2019-08-29
CA3049141A1 (en) 2018-08-02
AU2018213029B2 (en) 2020-11-05
PL3573983T3 (pl) 2021-10-04
HRP20211011T1 (hr) 2021-09-17
US10081625B2 (en) 2018-09-25
JP6738970B2 (ja) 2020-08-12
RS61979B1 (sr) 2021-07-30
EA201991515A1 (ru) 2020-01-16
UA123472C2 (uk) 2021-04-07
PE20191406A1 (es) 2019-10-04
TW201836607A (zh) 2018-10-16
AR110747A1 (es) 2019-05-02
KR20190096421A (ko) 2019-08-19
LT3573983T (lt) 2021-07-26
DOP2019000187A (es) 2019-08-15
MX2019008846A (es) 2019-09-10
IL267693B (en) 2021-08-31
AU2018213029A1 (en) 2019-07-04
CA3049141C (en) 2021-02-16
CN110198940B (zh) 2022-09-23
MD3573983T2 (ro) 2021-10-31
EA038368B1 (ru) 2021-08-17
JOP20190182B1 (ar) 2023-03-28
CY1124257T1 (el) 2022-07-22
EP3573983B1 (en) 2021-04-21
MX387166B (es) 2025-03-19
DK3573983T3 (da) 2021-06-28
JOP20190182A1 (ar) 2019-07-25
MY197494A (en) 2023-06-19
WO2018140299A1 (en) 2018-08-02
EP3573983A1 (en) 2019-12-04
JP2020504142A (ja) 2020-02-06
CO2019007711A2 (es) 2019-07-31
PT3573983T (pt) 2021-06-17
BR112019013535A2 (pt) 2020-01-07
MA47368B1 (fr) 2021-07-29
ECSP19053616A (es) 2019-08-30
ZA201904171B (en) 2022-01-26
SI3573983T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
AR103680A1 (es) Inhibidores selectivos de bace1
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
MX381224B (es) Potentes moduladores de gamma-secretasa.
MX394782B (es) Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial.
MX2017004569A (es) Inhibidores de gingipaina de lisina.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2021001273A (es) Métodos para tratar trastornos neurodegenerativos.
MX2016008968A (es) Compuestos organicos.
ECSP17071769A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
CR20170426A (es) Inhibidores de bace 1
BR112019023322A2 (pt) Sanfetrona ou um sal ou éster do mesmo para utilização no tratamento de infecção micobacteriana
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
RU2016108801A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера